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The human telomerase reverse transcriptase (hTERT)
promoter can be used for the tumor-specific expression of
transgenes in order to induce selective cancer cell death.
The hTERT core promoter is active in cancer cells but not
in normal cells. To examine whether the combination of
TNF-related apoptosis inducing ligand (TRAIL) treatment
and cancer cell-selective expression of the TRAIL-death
receptor could induce cell death in TRAIL-resistant cancer
cells, we generated a death receptor-4 (DR4)-expressing
adenovirus (Ad-hTERT-DR4), in which the expression of
DR4 is driven by the hTERT promoter. Upon infection,
DR4 expression was slightly increased in cancer cell lines,
and cell death was observed in TRAIL-resistant cancer cell
lines but not in normal human cells when DR4 infection
was combined with TRAIL treatment. We also generated an
adenovirus that expresses a secretable isoleucine zipper
(ILZ)-fused, extracellular portion of TRAIL (Ad-ILZ-
TRAIL). In cells infected with Ad-ILZ-TRAIL, TRAIL was
expressed, secreted, oligomerized and biologically active in
the induction of apoptosis in TRAIL-sensitive cancer cells.
When Ad-hTERT-DR4 infected TRAIL-resistant HCE4 cells
and Ad-ILZ-TRAIL infected TRAIL-resistant HCE7 cells
were co-cultured, cell deaths were evident 24 h after co-cul-
ture. Taken together, our results reveal that the combination
of TRAIL and cancer cell-specific expression of DR4 has
the potential to overcome the resistance of cancer cells to
TRAIL without inducing significant cell death in normal
cells.
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INTRODUCTION
Human telomerase is a ribonucleoprotein en-
zyme that is important for the maintenance of
telomeric structures at the ends of chromo-
somes.1-3 Telomerase activity is closely associated
with the expression of human telomerase reverse
transcriptase (hTERT). The expression of hTERT
RNA is detected at high levels in tumor tissues
and tumor-derived cell lines but not in normal
adjacent tissues or primary cells.
4-6
A 5' flanking
region of 341 bp in the hTERT gene was identified
as the minimal promoter region, containing ele-
ments responsible for its activity.
7,8
The dif-
ferential activity of this region in normal cells and
cancer cells opens the possibility of utilizing the
hTERT promoter for the selective expression of
apoptosis-inducing genes only in cancer cells.
TNF-related apoptosis inducing ligand (TRAIL)
is a promising agent for development as a cancer
therapeutic9 because it appears to specifically kill
transformed and cancer cells, whereas most nor-
mal cells appear to be resistant to TRAIL.
10,11
TRAIL induces apoptotic cell death upon binding
to either of two pro-apoptotic TRAIL receptors,
TRAIL R1 (DR4)12 or TRAIL R2 (KILLER/DR5).13
Although TRAIL has the potential to specifically
kill cancer cells, many cancer cells are TRAIL-
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resistant.14,15
Therefore, we performed this study to examine
whether the combination of TRAIL treatment
and cancer cell-selective expression of TRAIL
death receptor DR4 could induce cell death in
TRAIL-resistant cancer cells. We generated an
adenovirus expressing DR4 under the control of
the hTERT promoter to express DR4 selectively
in cancer cells. Here, we show that the hTERT
promoter is active in a variety of human cancer
cell lines but not in normal primary human
keratinocytes, and further that the tumor-specific
expression of DR4 induces apoptosis in TRAIL-
resistant cancer cells when combined with
TRAIL.
MATERIALS AND METHODS
Cell lines and culture
Normal human primary cervical epithelial cells
that were kindly provided by Dr. Young-Tae Kim
(Department of Obstetrics and Gynecology,
Yonsei University College of Medicine) were
grown in Keratinocyte-SFM medium (Gibco BRL,
Rockville, MD, USA) containing bovine pituitary
extract (40 g/mL) and epidermal growth factor (1μ
ng/mL). Cancer cell lines were grown as pre-
viously described.14,16
Recombinant human TRAIL and caspase inhibi-
tor treatments
Cells were treated with 100 ng/mL final concen-
tration of TRAIL
17
for 2 h. The irreversible pan
caspase inhibitor z-VAD-fmk (R&D Systems,
Minneapolis, MN, USA) was used at a final con-
centration of 20 M and was added 2 h prior toμ
the addition of TRAIL.
Cloning of the hTERT core promoter
The hTERT core promoter7 was amplified using
genomic DNA as a template. For the amplifica-
tion, the following primer pairs were used: Sense
primer, 5'-GAAGATCT GGAGAGCTGCGCTGT-
3' and anti-sense primer, 5'-GAAGATCTAAGCTT
GCCAGGGCTT-3'. The amplified (301 bp) hTERT
core promoter was cloned into the pGL3-basic
(Promega, Madison, WI, USA) vector and was
named pGL3-hTERT.
hTERT promoter activity assay
HCE4, CasKi, HCT116-neo, HCT116-E6, or
normal human primary cervical epithelial cells
were transiently transfected with pGL3-basic as
a negative control, pGL3-control as a positive
control, or pGL3-hTERT using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer's instructions. Briefly, 5 ×
105 cells seeded in a 6-well plate were exposed
to transfection mixtures containing 1.8 g of theμ
reporter plasmids and 0.2 g of pCMV-μ β
-galactosidase (BD Bioscience Clontech, Palo
Alto, CA, USA) for 5 h at 37 . Then, 3 mL of
growth media were added to the cells, followed
by incubation for an additional 16 h. The cells
were harvested 48 h after transfection. A lu-
ciferase assay was performed according to the
manufacturer's protocol (Promega). A -galacβ -
tosidase assay was performed to standardize
transfection efficiency. In cells infected with ade-
novirus, infections were carried out 24 h after
transfection.
Generation of adenoviruses
To make an adenovirus expressing full length
DR4 under the control of the hTERT core pro-
moter, the pShuttle-CMV (Stratagene, La Jolla,
CA, USA) vector was used. To obtain DR4 ex-
pression driven by the hTERT core promoter, the
CMV promoter in pShuttle-CMV was replaced by
a PCR amplified hTERT core promoter (pShuttle-
hTERT) and then full length DR4 cDNA was in-
serted into the pShuttle-hTERT (pShuttle-hTERT-
DR4) vector. Recombinant plasmid was generated
in BJ5183 E. coli by co-transforming PmeI-digested
pShuttle-hTERT-DR4 and pAdEASY.18 The recom-
binant plasmid was digested with PacI and was
used for transfection into 293 cells using Lipofec-
tamine 2000 (Invitrogen). Approximately 7 days
after transfection, the cells were harvested, and
the viruses were amplified and purified as pre-
viously described.
19
A TRAIL-expressing adeno-
virus was made using the extracellular portion of
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TRAIL (Aa 95 to 281), which can be secreted and
self-oligomerized. A DNA fragment that encodes
the secretion signal from the V-J2-C region of the
mouse Ig chain signal peptide, isoleucine zipperκ
(ILZ) fragment that was made by annealing two
synthetic oligonucleotides (5'-GGGGTACCATGA
AGCAGATCGAGGACAAAATT GAGGAAATCC
TGTCCAAGATTTACCACATCGAGAACGAGAT
CGCCCGGATTAAGAAACTCATTGGCGAGAAG
CTTGGG-3' and 5'-CCCAAGCTTCTCGCCAATG
AGTTTCTTAATCCGGGCGATCTCGTTCTCGAT
GTGGTAAATCTTGGACAGGATTTCCTCAATTTT
GTCCTCGATCTGCTTCATGGTACCCC-3') for self-
oligomerization20 and was sequentially inserted
into the pAdTRACK/CMV vector. An adenovirus
expressing the E6 ORF of human papillomavirus
(HPV) type 16 was generated (Ad-E6). An adeno-
virus expressing green fluorescence protein (GFP)
was also generated and used as a control virus
(Ad-GFP). The infectivity of viruses was checked
by the observation of green fluorescence within
infected cells using fluorescence microscopy. To
confirm the oligomerization of TRAIL, ethylene
glycol bis-(succinic acid) (EGS, final 1 mM; Sigma,
St. Louis, MO, U.S.A.) was used as a cross-linker
to maintain oligomeric structure during dena-
turing SDS-PAGE analysis.
Western blot immunostaining
Western blot analysis was carried out as pre-
viously described.14 Blotted membranes were im-
munostained with anti-DR4 (1:500, Pharmingen,
San Diego, CA, U.S.A.), anti-caspase-3 (E-8, 1:200;
Santa Cruz, Santa Cruz, CA, U.S.A.), anti-PARP
(1: 1,000; Cell Signaling Technology, Inc., Beverly,
MA, U.S.A.), anti-TRAIL (1:500; PeproTech Inc.,
Rocky Hill, NJ, U.S.A.), or anti- -tubulin (1:500;α
Oncogene Science, Cambridge, MA, U.S.A.).
Flow cytometric cell death analysis
Cells were harvested after the indicated treat-
ments and time points, stained with propidium
iodide, and analyzed by flow cytometry for sub-
G1 content as previously described.21 Cell sorting
was performed on a BD FACSCalibur (Becton
Dickinson, Boston, MA, U.S.A.).
RESULTS
hTERT core promoter activity in normal and
cancer cell lines
To examine the promoter activity of the hTERT
gene in normal human cervical keratinocytes or in
a TRAIL-resistant human esophageal cancer cell
line, HCE4, a luciferase activity assay was per-
formed. Transfection of pGL3-hTERT into HCE4
cells yielded a significant increase in promoter
activity compared to the transfection of the pGL3
basic control vector (Fig. 1B). Transfection of the
same construct into normal keratinocytes resulted
only in background levels of luciferase activity
(Fig. 1A). The E6 protein from HPV type 16 tran-
scriptionally transactivates the hTERT promoter;1
expectedly, hTERT promoter activity was mark-
edly increased in Ad-E6 infected cells (Fig. 1).
These results suggest that the hTERT promoter is
active only in cancer cells and that the presence
of E6 protein could augment hTERT promoter
activity.
Expression and secretion of TRAIL by TRAIL-
expressing adenovirus
We generated an adenovirus expressing the
isoleucine zipper (ILZ)-fused extracellular portion
of TRAIL (Ad-ILZ-TRAIL, Fig. 2A). To confirm
the expression, secretion, and oligomerization of
TRAIL, TRAIL-resistant HCE4 cells were infected
with Ad-ILZ-TRAIL. Two days after infection,
Western blot analysis was performed using cell
extracts and the media. In the cell extracts, both
un-processed and processed forms of TRAIL were
present, but in the media only the processed form
of the expressed TRAIL was present (Fig. 2B). The
oligomerization of the secreted TRAIL was con-
firmed by cross-linking followed by Western blot
analysis (Fig. 2C). The biological activity of TRAIL
was examined using TRAIL-sensitive SW480 colon
cancer cells. The cells infected with Ad-ILZ-TRAIL
were morphologically apoptotic (Fig. 2D, TR).
Procaspase-3 was activated and PARP was
cleaved in the cells infected with Ad- ILZ-TRAIL
but not in the presence of z-VAD-FMK (Fig. 2E.
lane 2 vs. 4). Together, these data suggest that
TRAIL expressed from the adenovirus is secreted,
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Fig. 1. hTERT core promoter activity in normal cells and cancer cells. The luciferase activity assay was performed using
extracts of cells transiently transfected with pGL3-basic, pGL3-control, or pGL3-hTERT vectors for 24 h. pCMV- -β
galactosidase was co-transfected in order to standardize the transfection efficiency. The data are expressed as the mean
± SD for triplicate conditions, and similar results were obtained from two independent experiments.
A B
Fig. 2. Expression-, secretion-, and apoptosis-inducing activity of adenoviral-encoded TRAIL. (A) Schematic diagrams of
Ad-GFP and Ad-ILZ-TRAIL. (B) Expression and secretion of TRAIL after infection. TRAIL-resistant TE5 cells were infected
with either Ad-GFP or Ad-ILZ-TRAIL (Ad-ILZ). Western blot analysis was performed using lysates and culture media 48
h after infection. The arrowhead indicates the un-processed signal peptide containing TRAIL and the arrow represents the
fully processed form of TRAIL. (C) Oligomerization of secreted TRAIL. The same media used in (B) was used to confirm
the oligomerization of secreted TRAIL. To maintain oligomerization of secreted TRAIL during SDS-PAGE, EGS (final 1
mM) was added into the media. (D) Apoptosis-inducing activities of expressed TRAIL. TRAIL-sensitive SW480 cells were
infected with either Ad-GFP (GFP) or Ad-ILZ-TRAIL (TR). After 48 h, the cells were observed under bright field (B) or
fluorescent (F) microscopy (× 400). (E) Western blot analysis was performed using the lysates obtained from the same
cells as in (D). z-VAD-fmk (20 M final) was added 1 h after infection.μ
A
B
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E
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oligomerized, and biologically active.
Cancer cell death induced by the combination of
TRAIL treatment and Ad-hTERT-DR4 infection
An adenovirus that expresses DR4 under the
control of the hTERT core promoter was gen-
erated (Fig. 3A). When infected into HCE4 or
CasKi cells, the expression level of DR4 was
slightly increased and the cells underwent apop-
tosis upon TRAIL treatment (Fig. 3B). Infection of
normal primary human cervical epithelial cells
with either Ad-GFP or Ad-hTERT-DR4 did not
result in cell death. The addition of TRAIL to
infected cells slightly increased cell death, but less
than 10% of the cells underwent apoptosis (Fig.
3C). Taken together, these results suggest that the
combination of TRAIL treatment and the infection
of an adenovirus expressing TRAIL-death receptor
DR4 under the control of the hTERT core promo-
ter has the potential to induce cell death in TRAIL-
resistant cancer cells but not in normal cells.
The bystander effect of TRAIL from Ad-ILZ-TR
To check the bystander effect of TRAIL pro-
A
B
C
Fig. 3. Cancer cell death induced by the
combination of TRAIL treatment and Ad-
hTERT-DR4 infection. (A) Schematic dia-
gram of Ad-hTERT DR4. (B) The expres-
sion of DR4 and induction of apoptosis in
cancer cell lines in the presence of TRAIL.
Western blot analysis was performed
using extracts of CasKi (top left) or HCE4
(top right) cells that had been infected
with either Ad-GFP or Ad-hTERT DR4 for
24 h and subsequently treated with human
recombinant TRAIL for 24 h. Flow cyto-
metric analysis for sub-G1 content. CasKi
or HCE4 cells were infected and treated
as in (B), and subsequently harvested for
flow cytometry. The sub-G1 content of
10,000 cells was examined for each sample
(bottom left). This experiment was per-
formed in triplicate. Percent of sub-G1
was plotted (bottom right). (C) Resistance
of normal primary cervical keratinocytes.
Normal keratinocytes were infected and
treated, and cell death was quantified by
flow cytometric detection as in (B). This
experiment was performed in triplicate.
Percent of sub-G1 was plotted.
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duced from the cells infected with Ad-ILZ-TRAIL,
TRAIL-resistant HCE4 cells were infected with
either Ad-GFP or Ad-hTERT DR4, and TRAIL-
resistant HCE7 cells16 were infected with either
Ad-GFP or Ad-ILZ-TRAIL. One day after the in-
fection, the cells were harvested and co-cultured
for 24 h. When Ad-hTERT DR4 infected HCE4
cells and Ad-ILZ-TRAIL infected HCE7 cells were
co-cultured, the induction of apoptosis was evi-
dent both morphologically (Fig. 4A) and bioche-
mically (Fig. 4B). These results suggest that DR4-
expressing cancer cells might be killed by the
bystander effect of TRAIL encoded by the
Ad-ILZ-TRAIL vector.
DISCUSSION
Although TRAIL is a potent inducer of apo-
ptosis in cancer cells, there are still several TRAIL-
resistant cancer cells. Many successful approaches
have been devised to overcome this resistance,
such as the combination of TRAIL with other
reagents like DNA damaging agents,14,22 ionizing
radiation,23 or virus expressing wild type p53.24 In
this study, we tested the effect of combining
TRAIL and hTERT core promoter-driven expres-
sion of DR4 on the induction of apoptosis in
TRAIL-resistant cancer cell lines and normal cells.
We found that the hTERT core promoter was able
to drive DR4 expression in cancer cells. The
combination of infection with a DR4-expressing
adenovirus and TRAIL treatment was able induce
apoptosis in TRAIL-resistant cancer cells without
inducing significant cell death in primary normal
cells. In addition, TRAIL expressed from an ade-
novirus could induce cell death in Ad-hTERT-DR4
infected TRAIL-resistant cancer cells by the
Fig. 4. The bystander effect of adenoviral-encoded
TRAIL. (A) Morphologic observation of apoptosis.
TRAIL-resistant HCE4 cells were infected with either
Ad-GFP (GFP) or Ad-hTERT DR4 (DR4), and TRAIL-
resistant HCE7 cells were infected with either Ad-GFP
or Ad-ILZ-TRAIL (TR). One day after the infection, the
cells were harvested and co-cultured for 24 h. The cells
were observed under bright field (B) or fluorescent (F)
microscopy (× 100). (B) Biochemical detection of apo-
ptosis. Western blot analysis was performed using the
extracts obtained from the cells described in (A).
A
B
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bystander effect.
The hTERT promoter was widely used for
inducing apoptosis selectively in cancer cells by
driving expression of apoptosis-inducing gene
products such as bax or TRAIL.25-30 However, the
expression of TRAIL alone could only induce
apoptosis in TRAIL-sensitive cancer cells and the
expression of bax alone could induce apoptosis
only in cancer cells that were infected with the
adenoviruses. Accordingly, the combined use of
the adenovirus that could express TRAIL-death
receptor selectively in cancer cells and the ade-
novirus that could express TRAIL which is then
secreted into adjacent cancer cells, thereby ex-
erting the bystander effect, may induce apoptosis
in clumps of cancer cells that are resistant to
TRAIL. Thus, the generation of an adenovirus that
could bicistronically express the death receptor
and TRAIL under the control of the hTERT
promoter could reduce the number of viral par-
ticles used in the experiment, thereby alleviating
adenoviral toxicity toward normal cells.
The strategy introduced in this experiment for
inducing cancer cell death could be applied to the
treatment of cervical cancer because many cervical
cancers are associated with the infection of
oncogenic HPV, such as types 16 and 18, which
can transform normal cells by expressing E6 and
E7 oncoproteins.
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